Screener
Beta Bionics BBNX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of long-term investments | (44,812) | (31,069) |
| Proceeds from maturities and redemptions of short-term investments | 96,000 | 51,000 |
| Purchases of property and equipment | (2,416) | (2,112) |
| Net cash provided by (used in) investing activities | 48,772 | (172,949) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs | — | 195,430 |
| Proceeds from the issuance of common stock from private placement, net of issuance costs | — | 15,591 |
| Proceeds from stock option exercises and employee stock purchase plan issuances | 2,424 | 140 |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's investing cash flow?
- Beta Bionics (BBNX) reported investing cash flow of $26.93M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Beta Bionics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude